Taysha Gene Therapies
51 articles with Taysha Gene Therapies
-
Taysha Gene Therapies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
3/28/2023
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) today reported financial results for the fourth quarter and full-year ended December 31, 2022, and provided a corporate update.
-
Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 28
3/15/2023
Taysha Gene Therapies, Inc. announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2022, and host a corporate update conference call and webcast on Tuesday, March 28, 2023, at 4:30 PM Eastern Time.
-
The FDA asked Taysha Gene Therapies to dose more patients in a double-blinded, placebo-controlled trial before submitting a BLA for its giant axonal neuropathy candidate.
-
Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy and a 2023 Corporate Outlook
1/31/2023
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical -stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic rare diseases of the central nervous system (CNS), today provided an update on the TSHA-120 program in giant axonal neuropathy (GAN) and a corporate outlook for 2023.
-
Taysha Gene Therapies Announces Executive Leadership Changes
12/16/2022
Taysha Gene Therapies, Inc., a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, announced executive leadership changes effective immediately.
-
Taysha Gene Therapies to Participate in JMP Securities Hematology and Oncology Summit
11/29/2022
Taysha Gene Therapies, Inc. announced that it will participate in the JMP Securities Hematology and Oncology Summit, which is taking place virtually from Tuesday, December 6, 2022, through Wednesday, December 7, 2022.
-
Taysha Gene Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
11/8/2022
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
-
Taysha Gene Therapies to Release Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 8
11/2/2022
Taysha Gene Therapies, Inc. announced that it will report its financial results for the third quarter ended September 30, 2022, and host a corporate update conference call and webcast on Tuesday, November 8, 2022, at 8:00 AM Eastern Time.
-
Taysha Announces Pricing of Public Offering of Common Stock - October 26, 2022
10/26/2022
Taysha Gene Therapies, Inc. announced the pricing of an underwritten public offering of 14,000,000 shares of its common stock at a price to the public of $2.00 per share.
-
Taysha Gene Therapies has entered into a strategic equity investment and licensing deal with Astellas. The latter stands to gain access to Taysha’s gene therapy development programs for Rett syndrome and GAN.
-
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock - October 25, 2022
10/25/2022
Taysha Gene Therapies, Inc. announced that it intends to offer and sell, subject to market conditions, $30 million of shares of its common stock in an underwritten public offering.
-
Taysha Gene Therapies to Host Conference Call to Discuss Astellas Pharma’s Strategic Investment to Support the Development of Taysha’s AAV-based Gene Therapy Programs
10/24/2022
Taysha Gene Therapies, Inc. announced that it will host a conference call and webcast with slides to discuss Astellas Pharma’s strategic investment to support the development of two of Taysha’s AAV-based gene therapy programs, TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy, on Tuesday, October 25, 2022, at 8:00 AM Eastern Time.
-
Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha’s AAV-based Gene Therapy Programs
10/24/2022
Astellas Pharma Inc. and Taysha Gene Therapies, Inc. announced a strategic investment to support the advancement of Taysha’s adeno-associated virus gene therapy development programs for the treatment of Rett syndrome and GAN.
-
Taysha Gene Therapies Announces Presentations at the Upcoming 29th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT)
10/6/2022
Taysha Gene Therapies, Inc. today announced two poster presentations at the upcoming 29th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT) in cooperation with the British Society of Gene & Cell Therapy (BSGCT) taking place in Edinburgh, Scotland from October 11-14, 2022.
-
FUJIFILM Dyosynth Biotechnologies, Taysha Gene Therapies, Veravas highlight innovation stemming from the Lone Star state. BioSpace takes a deep dive into these and other Texas innovators.
-
Taysha Gene Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8/11/2022
Taysha Gene Therapies, Inc. today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update.
-
Taysha Gene Therapies to Release Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11
8/9/2022
Taysha Gene Therapies, Inc. announced that it will report its financial results for the second quarter ended June 30, 2022, and host a corporate update conference call and webcast on Thursday, August 11, 2022, at 8:00 AM Eastern Time.
-
Taysha Gene Therapies to Participate in Upcoming August Investor Conferences
8/1/2022
Taysha Gene Therapies, Inc. today announced its participation in panel discussions at the BTIG Biotechnology Conference on August 8th and the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 10th.
-
Taysha Gene Therapies Announces Annual Stockholder MeetingThe Annual Stockholder Meeting on Friday, June 17, 2022 at 10 am ET
6/13/2022
Taysha Gene Therapies, Inc. today announced that its annual stockholder meeting will be held on Friday, June 17, 2022 at 10 am ET via webcast.
-
Taysha Gene Therapies to Participate in Upcoming June 2022 Investor Conferences and Convention
6/2/2022
Taysha Gene Therapies, Inc. announced its participation in a fireside chat at the Jefferies Healthcare Conference, Goldman Sachs 43rd Annual Global Healthcare Conference, and JMP Securities Life Sciences Conference.